Opthea, an Australian Phase 3 biotech developing VEGF inhibitors for wet AMD, raised $128 million by offering 9.5 million ADS equivalents at $13.50, below the as-converted last close of its shares on the ASX (OPT). The ADS equivalents offered consisted of 8.6 million ADSs and pre-funded warrants to purchase 0.9 million ADSs, sold to certain investors.
Opthea plans to list on the Nasdaq under the symbol OPT. Citi and SVB Leerink acted as joint bookrunners on the deal.
